tetano
Editor, Senior Moderator
Nat Commun
. 2021 Aug 17;12(1):5061.
doi: 10.1038/s41467-021-25167-5.
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
Donal T Skelly[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Adam C Harding[SUP] #[/SUP][SUP] 4 [/SUP], Javier Gilbert-Jaramillo[SUP] 4 [/SUP], Michael L Knight[SUP] 4 [/SUP], Stephanie Longet[SUP] 5 6 [/SUP], Anthony Brown[SUP] 1 [/SUP], Sandra Adele[SUP] 1 [/SUP], Emily Adland[SUP] 7 [/SUP], Helen Brown[SUP] 1 [/SUP], Medawar Laboratory Team; Tom Tipton[SUP] 5 6 [/SUP], Lizzie Stafford[SUP] 8 [/SUP], Alexander J Mentzer[SUP] 6 8 [/SUP], Síle A Johnson[SUP] 3 9 [/SUP], Ali Amini[SUP] 1 3 10 [/SUP], OPTIC (Oxford Protective T cell Immunology for COVID-19) Clinical Group; Tiong Kit Tan[SUP] 11 [/SUP], Lisa Schimanski[SUP] 11 12 [/SUP], Kuan-Ying A Huang[SUP] 13 [/SUP], Pramila Rijal[SUP] 11 12 [/SUP], PITCH (Protective Immunity T cells in Health Care Worker) Study Group; C-MORE/PHOSP-C Group; John Frater[SUP] 1 3 [/SUP], Philip Goulder[SUP] 7 [/SUP], Christopher P Conlon[SUP] 8 [/SUP], Katie Jeffery[SUP] 3 [/SUP], Christina Dold[SUP] 14 15 [/SUP], Andrew J Pollard[SUP] 14 15 [/SUP], Alex Sigal[SUP] 16 17 18 [/SUP], Tulio de Oliveira[SUP] 17 19 20 21 [/SUP], Alain R Townsend[SUP] 11 12 [/SUP], Paul Klenerman[SUP] 1 3 10 15 [/SUP], Susanna J Dunachie[SUP] 1 3 22 23 [/SUP], Eleanor Barnes[SUP] #[/SUP][SUP] 1 3 10 15 [/SUP], Miles W Carroll[SUP] #[/SUP][SUP] 5 6 [/SUP], William S James[SUP] #[/SUP][SUP] 24 [/SUP]
Collaborators, Affiliations
Abstract
The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020. We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine. Importantly, high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. Vaccination is required to generate high potency immune responses to protect against these and other emergent variants.
. 2021 Aug 17;12(1):5061.
doi: 10.1038/s41467-021-25167-5.
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
Donal T Skelly[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Adam C Harding[SUP] #[/SUP][SUP] 4 [/SUP], Javier Gilbert-Jaramillo[SUP] 4 [/SUP], Michael L Knight[SUP] 4 [/SUP], Stephanie Longet[SUP] 5 6 [/SUP], Anthony Brown[SUP] 1 [/SUP], Sandra Adele[SUP] 1 [/SUP], Emily Adland[SUP] 7 [/SUP], Helen Brown[SUP] 1 [/SUP], Medawar Laboratory Team; Tom Tipton[SUP] 5 6 [/SUP], Lizzie Stafford[SUP] 8 [/SUP], Alexander J Mentzer[SUP] 6 8 [/SUP], Síle A Johnson[SUP] 3 9 [/SUP], Ali Amini[SUP] 1 3 10 [/SUP], OPTIC (Oxford Protective T cell Immunology for COVID-19) Clinical Group; Tiong Kit Tan[SUP] 11 [/SUP], Lisa Schimanski[SUP] 11 12 [/SUP], Kuan-Ying A Huang[SUP] 13 [/SUP], Pramila Rijal[SUP] 11 12 [/SUP], PITCH (Protective Immunity T cells in Health Care Worker) Study Group; C-MORE/PHOSP-C Group; John Frater[SUP] 1 3 [/SUP], Philip Goulder[SUP] 7 [/SUP], Christopher P Conlon[SUP] 8 [/SUP], Katie Jeffery[SUP] 3 [/SUP], Christina Dold[SUP] 14 15 [/SUP], Andrew J Pollard[SUP] 14 15 [/SUP], Alex Sigal[SUP] 16 17 18 [/SUP], Tulio de Oliveira[SUP] 17 19 20 21 [/SUP], Alain R Townsend[SUP] 11 12 [/SUP], Paul Klenerman[SUP] 1 3 10 15 [/SUP], Susanna J Dunachie[SUP] 1 3 22 23 [/SUP], Eleanor Barnes[SUP] #[/SUP][SUP] 1 3 10 15 [/SUP], Miles W Carroll[SUP] #[/SUP][SUP] 5 6 [/SUP], William S James[SUP] #[/SUP][SUP] 24 [/SUP]
Collaborators, Affiliations
- PMID: 34404775
- DOI: 10.1038/s41467-021-25167-5
Abstract
The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020. We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine. Importantly, high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. Vaccination is required to generate high potency immune responses to protect against these and other emergent variants.